NasdaqGM - Nasdaq Real Time Price USD

Evolus, Inc. (EOLS)

11.50 +0.04 (+0.35%)
As of 10:59 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David Moatazedi President, CEO & Director 1.27M -- 1978
Ms. Sandra Beaver Chief Financial Officer 372.23k -- 1978
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. Chief Medical Officer and Head of Research & Development 682.03k -- 1962
Mr. Nareg Sagherian Head of Global Investor Relations & Corporate Communications -- -- --
Mr. Jeffrey J. Plumer General Counsel -- -- --
Mr. Kurt Knab Vice President of Sales -- -- --
Ms. Tomoko Yamagishi-Dressler Chief Marketing Officer -- -- --
Ms. Jessica Novak Senior Vice President of Human Resources -- -- --

Evolus, Inc.

520 Newport Center Drive
Suite 1200
Newport Beach, CA 92660
United States
(949) 284-4555 https://www.evolus.com
Sector: 
Healthcare
Full Time Employees: 
273

Description

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Corporate Governance

Evolus, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024
Evolus, Inc. Earnings Call

Related Tickers

DCPH Deciphera Pharmaceuticals, Inc.
14.38
+1.41%
 
AVDL Avadel Pharmaceuticals plc
17.99
+0.93%
 
DVAX Dynavax Technologies Corporation
11.17
0.00%
 
ESPR Esperion Therapeutics, Inc.
1.9350
-2.76%
 
ELAN Elanco Animal Health Incorporated
13.33
+2.22%
 
VTRS Viatris Inc.
11.55
+0.65%
 
BHC Bausch Health Companies Inc.
8.73
+1.28%
 
HROW Harrow, Inc.
10.52
+5.17%
 
IRWD Ironwood Pharmaceuticals, Inc.
8.05
-0.43%
 
ETON Eton Pharmaceuticals, Inc.
3.5500
+13.83%